PHARVARIS NV

Pharvaris N.V. is a clinical-stage biopharmaceutical company whose primary business activity is the development of novel oral bradykinin B2 receptor antagonists for treating hereditary angioedema and other bradykinin-mediated disorders. The company’s drug development pipeline relies on preclinical animal testing as a standard and necessary component of its research and development process.

In its public SEC filings, Pharvaris explicitly acknowledges that animal testing is integral to its operations, stating that an inability to conduct such testing “could harm our research and development activities.” The company further notes that these activities have been the subject of controversy and adverse publicity from animal rights groups. Pharvaris reports observing effects of its drug candidates “in preclinical animal” models, confirming the ongoing exploitation of animals within its development workflow. This reliance places the company within the broad category of commercial animal exploitation for product testing and development.